223 related articles for article (PubMed ID: 25496150)
21. Toward a Synergistic Operating Model for Westmead Research Hub Biobanks: A Questionnaire Study.
St George G; Wang XM; Linton J; Douglas N; Carpenter JE; Clarke CL; Heads JA
Biopreserv Biobank; 2019 Dec; 17(6):570-576. PubMed ID: 31429584
[TBL] [Abstract][Full Text] [Related]
22. Biobank Finances: A Socio-Economic Analysis and Review.
Gee S; Oliver R; Corfield J; Georghiou L; Yuille M
Biopreserv Biobank; 2015 Dec; 13(6):435-51. PubMed ID: 26697914
[TBL] [Abstract][Full Text] [Related]
23. Recommendations for a Dutch Sustainable Biobanking Environment.
van der Stijl R; Manders P; Eijdems EWHM
Biopreserv Biobank; 2021 Jun; 19(3):228-240. PubMed ID: 34042498
[TBL] [Abstract][Full Text] [Related]
24. A practical tool for modeling biospecimen user fees.
Matzke L; Dee S; Bartlett J; Damaraju S; Graham K; Johnston R; Mes-Masson AM; Murphy L; Shepherd L; Schacter B; Watson PH
Biopreserv Biobank; 2014 Aug; 12(4):234-9. PubMed ID: 25162459
[TBL] [Abstract][Full Text] [Related]
25. Cost model for biobanks.
Gonzalez-Sanchez MB; Lopez-Valeiras E; Morente MM; Fernández Lago O
Biopreserv Biobank; 2013 Oct; 11(5):272-7. PubMed ID: 24835258
[TBL] [Abstract][Full Text] [Related]
26. Sustainability of Biobanks in the Future.
De Souza YG
Adv Exp Med Biol; 2015; 864():29-35. PubMed ID: 26420611
[TBL] [Abstract][Full Text] [Related]
27. Bridging the financial gap through providing contract services: a model for publicly funded clinical biobanks.
Kozlakidis Z; Mant C; Cason J
Biopreserv Biobank; 2012 Aug; 10(4):357-60. PubMed ID: 24849884
[TBL] [Abstract][Full Text] [Related]
28. Business Planning in Biobanking: How to Implement a Tool for Sustainability.
Ciaburri M; Napolitano M; Bravo E
Biopreserv Biobank; 2017 Feb; 15(1):46-56. PubMed ID: 27898226
[TBL] [Abstract][Full Text] [Related]
29. Inter- and intra-biobank networks: classification of biobanks.
Shickle D; Griffin M; El-Arifi K
Pathobiology; 2010; 77(4):181-90. PubMed ID: 20616613
[TBL] [Abstract][Full Text] [Related]
30. "Forward-Thinking" in U.S. Biobanking.
Cadigan RJ; Edwards TP; Lassiter D; Davis AM; Henderson GE
Genet Test Mol Biomarkers; 2017 Mar; 21(3):148-154. PubMed ID: 28118036
[TBL] [Abstract][Full Text] [Related]
31. Nordic biological specimen banks as basis for studies of cancer causes and control--more than 2 million sample donors, 25 million person years and 100,000 prospective cancers.
Pukkala E; Andersen A; Berglund G; Gislefoss R; Gudnason V; Hallmans G; Jellum E; Jousilahti P; Knekt P; Koskela P; Kyyrönen PP; Lenner P; Luostarinen T; Löve A; Ogmundsdóttir H; Stattin P; Tenkanen L; Tryggvadóttir L; Virtamo J; Wadell G; Widell A; Lehtinen M; Dillner J
Acta Oncol; 2007; 46(3):286-307. PubMed ID: 17450464
[TBL] [Abstract][Full Text] [Related]
32. Biospecimen User Fees: Global Feedback on a Calculator Tool.
Matzke LA; Babinszky S; Slotty A; Meredith A; Castillo-Pelayo T; Henderson MK; Simeon-Dubach D; Schacter B; Watson PH
Biopreserv Biobank; 2017 Feb; 15(1):57-64. PubMed ID: 27576065
[TBL] [Abstract][Full Text] [Related]
33. Report on financing the new model of family medicine.
Spann SJ;
Ann Fam Med; 2004 Dec; 2 Suppl 3(Suppl 3):S1-21. PubMed ID: 15654084
[TBL] [Abstract][Full Text] [Related]
34. A Model to Estimate Frozen Tissue Collection Targets in Biobanks to Support Cancer Research.
Meredith AJ; Slotty A; Matzke L; Babinszky S; Watson PH
Biopreserv Biobank; 2015 Oct; 13(5):356-62. PubMed ID: 26418967
[TBL] [Abstract][Full Text] [Related]
35. Nordic biological specimen bank cohorts as basis for studies of cancer causes and control: quality control tools for study cohorts with more than two million sample donors and 130,000 prospective cancers.
Pukkala E
Methods Mol Biol; 2011; 675():61-112. PubMed ID: 20949384
[TBL] [Abstract][Full Text] [Related]
36. Market-driven production of biospecimens and the role of NHS hospital-led biobanks.
Timmons S; Vezyridis P
Sociol Health Illn; 2017 Sep; 39(7):1242-1257. PubMed ID: 28555937
[TBL] [Abstract][Full Text] [Related]
37. Transparency of Biobank Access in Canada: An Assessment of Industry Access and the Availability of Information on Access Policies and Resulting Research.
Gibson SG; Axler RE; Lemmens T
J Empir Res Hum Res Ethics; 2017 Dec; 12(5):310-325. PubMed ID: 28818009
[TBL] [Abstract][Full Text] [Related]
38. How Many Health Research Biobanks Are There?
O'Donoghue S; Dee S; Byrne JA; Watson PH
Biopreserv Biobank; 2022 Jun; 20(3):224-228. PubMed ID: 34582255
[No Abstract] [Full Text] [Related]
39. Fee-for-service as a business model of growing importance: the academic biobank experience.
McDonald SA; Sommerkamp K; Egan-Palmer M; Kharasch K; Holtschlag V
Biopreserv Biobank; 2012 Oct; 10(5):421-5. PubMed ID: 23386922
[TBL] [Abstract][Full Text] [Related]
40. Improving Academic Biobank Value and Sustainability Through an Outputs Focus.
Rush A; Catchpoole DR; Ling R; Searles A; Watson PH; Byrne JA
Value Health; 2020 Aug; 23(8):1072-1078. PubMed ID: 32828220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
